ISOFOL Stock Overview
A clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Isofol Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.41 |
| 52 Week High | SEK 4.89 |
| 52 Week Low | SEK 0.52 |
| Beta | 1.93 |
| 1 Month Change | -27.56% |
| 3 Month Change | -7.85% |
| 1 Year Change | 330.23% |
| 3 Year Change | -72.98% |
| 5 Year Change | -87.54% |
| Change since IPO | -91.09% |
Recent News & Updates
Recent updates
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow
Jul 12
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued
May 18Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation
Nov 09Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?
May 12Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)
Apr 08Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment
Mar 03We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully
Jan 10
Shareholder Returns
| ISOFOL | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 3.7% | 1.1% | -3.3% |
| 1Y | 330.2% | 14.6% | 4.8% |
Return vs Industry: ISOFOL exceeded the Swedish Biotechs industry which returned 14.6% over the past year.
Return vs Market: ISOFOL exceeded the Swedish Market which returned 4.8% over the past year.
Price Volatility
| ISOFOL volatility | |
|---|---|
| ISOFOL Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ISOFOL's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ISOFOL's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 4 | Petter Lindqvist | isofolmedical.com |
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.
Isofol Medical AB (publ) Fundamentals Summary
| ISOFOL fundamental statistics | |
|---|---|
| Market cap | SEK 388.44m |
| Earnings (TTM) | -SEK 39.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.9x
P/E RatioIs ISOFOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISOFOL income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 37.30m |
| Gross Profit | -SEK 37.29m |
| Other Expenses | SEK 1.98m |
| Earnings | -SEK 39.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ISOFOL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 21:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Isofol Medical AB (publ) is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ulrik Trattner | Carnegie Investment Bank AB |
| Ole-Andreas Krohn | DNB Markets |
| David Martinsson | DNB Markets |